A Guardian investigation finds 419 GLP-1 prescriptions, including Wegovy and Mounjaro, were issued to children under 18 in England in 2025-26, ten of them to under-12s, and says the figures are likely a considerable underestimate. The prescriptions come through specialist NHS obesity clinics, whose doctors say the drugs are reserved for severely obese children unhelped by standard care, while new WHO guidelines advise against GLP-1s for under-10s and experts urge specialist support and monitoring.